Please ensure Javascript is enabled for purposes of website accessibility
ORIGINAL PAPER
Assessment of concentrations of interleukin-25 in bronchial asthma – preliminary studies
 
More details
Hide details
1
Department of Family Medicine and Geriatrics, Institute of Medical Sciences, Faculty of Medicine and Health Science, Jan Kochanowski University, Kielce, Poland
 
2
Tumor Marker Facility, Świętokrzyskie Oncology Centre, Kielce, Poland
 
 
Submission date: 2016-05-31
 
 
Final revision date: 2016-09-02
 
 
Acceptance date: 2016-10-10
 
 
Publication date: 2016-12-28
 
 
Medical Studies 2016;32(4):269-273
 
KEYWORDS
TOPICS
ABSTRACT
Introduction: Studies have demonstrated an important role of cytokines in the development of asthma, in particular the balance between them disturbed in favour of pro-inflammatory cytokines. Interleukin-25 (IL-25) belongs to the family of cytokines from IL-17. Its role in the pathogenesis of allergic diseases of the respiratory tract is not entirely clear. The study took into account the fact that the role can be very important due to the dual mechanism of action as an anti-inflammatory and inflammatory stimulant.
Aim of the research: To assess whether the concentration of IL-25 depends on the the severity of the course of asthma.
Material and methods: The study involved 80 people: 20 volunteers and 60 patients with asthma – 20 people with mild persistent asthma, 20 with moderate, and with 20 severe. All patients were maintained on a course of asthma control. From each patient, blood was drawn to assess IL-25 ELISA test; all patients also had spirometry performed (in the framework of visits to the clinic).
Results: In none of the cases of the people from the examined group there was an increased level of IL-25. However, some subjects (17) had higher levels of this interleukin than other people – among these were four volunteers and 13 patients with asthma.
Conclusions: In the future patients should be checked during exacerbations of asthma and have the response time tried to be extended to maximum so that we can measure lower concentrations, which within a standard procedure could has not been varied (found below the lowest standard).
REFERENCES (19)
1.
Światowa strategia rozpoznawania, leczenia i prewencji astmy (GINA). Medycyna Praktyczna, wydanie specjalne 2007; 1: 21-7.
 
2.
Bobrowski M, Kuna P, Pietruczuk M. The role of chemokines in asthma. J Labor Diagn 2011; 3: 323-30.
 
3.
Desai D, Brightling C. Cytokine and anti-cytokine therapy in asthma: ready for the clinic? Clin Exp Immunol 2009; 158: 10-9.
 
4.
Seys SF, Grabowski M, Adriaensen W, Decraene A, Dilissen E, Vanoirbeek JA, Dupont U, Ceuppens JL, Bullens IM. Sputum cytokine mapping reveals an “IL-5, IL-17A, IL-25” – high pattern associated with poorly controlled asthma. Clin Exp Allergy 2013; 43: 1009-17.
 
5.
Gołąb J, Jakóbisiak M, Lasek W. Immunologia. Wydawnictwo Naukowe PWN, Warsaw 2002; 198-221.
 
6.
Czarny-Dzialak M, Gluszek S. Stężenie IL-17 w surowicy w przebiegu ostrego zapalenia trzustki z uwzględnieniem stopnia ciężkości choroby. Prz Gastroenterol 2009; 4: 31-40.
 
7.
Czarny-Dzialak M, Gluszek S. The role of interleukine-25 in the pathogenesis of intensines’ and airways’ inflammation diseases. Studia Medyczne 2010; 16: 29-31.
 
8.
Stock P, Lombardi V, Kohlrautz V, Akbari O. Introduction of airway hyperreactivity by IL-25 is dependent on a subset of invariant NKT cells expressing IL-17RB. J Immunol 2009; 182: 5116-22.
 
9.
Wang YH, Liu YJ. Thymic stromal lymphopoietin, OX40-Iigand, and interleukin-25 in allergic responses. Clin Exp Allergy 2009; 39: 798-806.
 
10.
Miossec P, Korn T, Kuchroo VK. lnterleukin-17 and type 17 helper T cells. N Engl J Med 2009; 9: 888-98.
 
11.
Hurst SD, Muchamuel T, Gorman DM, Gilbert JM, Clifford T, Kwan S, Menon S, Seymour B, Jackson C, Kung TT, Brieland JK, Zurawski SM, Chapman RW, Zurawski G, Coffman RL. New IL-17 family members promote Th1 or Th2 responses in the lung: in vivo function of the novel cytokine 11-25. J Immunol 2002; 169: 443-53.
 
12.
Graczyk M, Bartuzi Z. Zapalenie eozynofilowe przewodu pokarmowego – rola komórek kwasochłonnych. Prz Gastroenterol 2007; 2: 230-4.
 
13.
Barlow JL, McKenzie AN. IL-25: a key requirement for the regulation of type-2 immunity. Biofactors 2009; 35: 178-82.
 
14.
Tang W, Smith SG, Beaudin S, Dua B, Howie K, Gauvreau G, O’Byrne PM. Ekspresja receptora IL-25 i IL-25 na eozynofilach u pacjentów z astmą alergiczną. Int Arch Allergy Immunol 2014; 163: 5-10.
 
15.
Cheng D, Xue Z, Yi L, Shi H, Zhang K, Huo X, Bonser LR, Zhao J, Xu Y, Erie OJ, Zhen G. Epithelial interleukin-25 is a key mediator in Th2-high, corticosteroid-responsive asthma. Am J Respir Crit Care Med 2014; 190: 639-48.
 
16.
Czarny-Dzialak M, Gluszek S. Czy IL-25 może stanowić wspólne ogniwo patomechanizmu łączące astmę i alergiczny nieżyt nosa? Studia Medyczne 2011; 27: 65-8.
 
17.
Corren J, Mansfield LE, Pertseva T, Blahzko V, Kaiser K. Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma. Respir Med 2013; 107: 180-95.
 
18.
Tan RA, Corren J. Clinical utility and development of the fluticasone/formoterol combination formulation (Fiutiform) for the treatment of asthma. Drug Des Devel Ther 2014; 8: 1555-61.
 
19.
Radhakrishna N, Tay TR, Hore-Lacy F, Hoy R, Dabscheck E, Hew M. Profile of difficult to treat asthma patients referred for systematic assessment. Respir Med 2016; 117: 166-73.
 
eISSN:2300-6722
ISSN:1899-1874
Journals System - logo
Scroll to top